Rituximab (MabThera) til behandling af aktiv reumatoid artritis

Daniel El Fassi; Claus Henrik Nielsen; Klaus Bendtzen

Rituximab (MabThera) til behandling af aktiv reumatoid artritis

Translated title of the contribution: [Rituximab (MabThera) as treatment of active rheumatoid arthritis]

Daniel El Fassi, Claus Henrik Nielsen, Klaus Bendtzen

4 Citations (Scopus)

Abstract

Rituximab (RTX) is a murine/human monoclonal antibody to CD20, a protein expressed almost exclusively on human B-lymphocytes. RTX induces rapid and marked B-cell depletion with beneficial clinical effects in 1/3 to 1/2 of rheumatoid arthritis patients. Treatment is given as two iv. infusions with a two-week interval and in combination with methotrexate. Mild to moderate side-effects are frequent, particularly during the first infusion, but long-term side-effects are generally rare, although pulmonary events and reactivation of viral infections of the liver is of concern.

Translated title of the contribution	[Rituximab (MabThera) as treatment of active rheumatoid arthritis]
Original language	Danish
Journal	Ugeskrift for Laeger
Volume	168
Issue number	47
Pages (from-to)	4079-81
Number of pages	3
ISSN	0041-5782
Publication status	Published - 20 Nov 2006

Cite this

@article{467775af423746da83651e4aebdd17c3,

title = "Rituximab (MabThera) til behandling af aktiv reumatoid artritis",

abstract = "Rituximab (RTX) is a murine/human monoclonal antibody to CD20, a protein expressed almost exclusively on human B-lymphocytes. RTX induces rapid and marked B-cell depletion with beneficial clinical effects in 1/3 to 1/2 of rheumatoid arthritis patients. Treatment is given as two iv. infusions with a two-week interval and in combination with methotrexate. Mild to moderate side-effects are frequent, particularly during the first infusion, but long-term side-effects are generally rare, although pulmonary events and reactivation of viral infections of the liver is of concern.",

author = "{El Fassi}, Daniel and Nielsen, {Claus Henrik} and Klaus Bendtzen",

year = "2006",

month = nov,

day = "20",

language = "Dansk",

volume = "168",

pages = "4079--81",

journal = "Ugeskrift for Laeger",

issn = "0041-5782",

publisher = "Almindelige Danske Laegeforening",

number = "47",

}

TY - JOUR

T1 - Rituximab (MabThera) til behandling af aktiv reumatoid artritis

AU - El Fassi, Daniel

AU - Nielsen, Claus Henrik

AU - Bendtzen, Klaus

PY - 2006/11/20

Y1 - 2006/11/20

N2 - Rituximab (RTX) is a murine/human monoclonal antibody to CD20, a protein expressed almost exclusively on human B-lymphocytes. RTX induces rapid and marked B-cell depletion with beneficial clinical effects in 1/3 to 1/2 of rheumatoid arthritis patients. Treatment is given as two iv. infusions with a two-week interval and in combination with methotrexate. Mild to moderate side-effects are frequent, particularly during the first infusion, but long-term side-effects are generally rare, although pulmonary events and reactivation of viral infections of the liver is of concern.

AB - Rituximab (RTX) is a murine/human monoclonal antibody to CD20, a protein expressed almost exclusively on human B-lymphocytes. RTX induces rapid and marked B-cell depletion with beneficial clinical effects in 1/3 to 1/2 of rheumatoid arthritis patients. Treatment is given as two iv. infusions with a two-week interval and in combination with methotrexate. Mild to moderate side-effects are frequent, particularly during the first infusion, but long-term side-effects are generally rare, although pulmonary events and reactivation of viral infections of the liver is of concern.

M3 - Tidsskriftartikel

SN - 0041-5782

VL - 168

SP - 4079

EP - 4081

JO - Ugeskrift for Laeger

JF - Ugeskrift for Laeger

IS - 47

ER -

Rituximab (MabThera) til behandling af aktiv reumatoid artritis

Abstract

Fingerprint

Cite this